Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan  by Lêng, Chhian Hūi et al.
Schizophrenia Research 171 (2016) 97–102
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresEstimation of life expectancy, loss-of-life expectancy, and lifetime
healthcare expenditures for schizophrenia in TaiwanChhian Hūi Lêng a,b, Ming Hui Chou c,d, Sheng-Hsiang Lin e, Yen Kuang Yang f, Jung-Der Wang c,g,⁎
a Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
b School of Medical Sociology and Social Work, Chung Shan Medical University, 402 Taichung, Taiwan
c Institute of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
d Psychiatric Hospital, Home of Philanthropy, Tainan 712, Taiwan
e Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
f Department of Psychiatry, National Cheng Kung University and Hospital, Tainan 701, Taiwan
g Departments of Occupational and Environmental Medicine and Internal Medicine, National Cheng Kung University Hospital, Tainan 701, Taiwan⁎ Corresponding author at: Institute of Public Health
Cheng Kung University, No. 1, University Road, Tainan Cit
E-mail address: jdwang121@gmail.com (J.-D. Wang).
http://dx.doi.org/10.1016/j.schres.2016.01.033
0920-9964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 17 April 2015
Received in revised form 30 December 2015
Accepted 15 January 2016
Available online 23 January 2016By employing a novel semi-parametric extrapolation method, the life expectancies after the ﬁrst hospitalization
for schizophrenia and the associated lifetime healthcare expenditures were both estimated. Based on the linkage
between the National Health Insurance Research Database and the National Mortality Registry of Taiwan, we
have established a schizophrenic cohort for 2000–2010 and followedup to 2011. Survival functionwas estimated
through Kaplan–Meier's method and extrapolated throughout life. We applied a simple linear regression to the
logit-transformed survival ratio between the schizophrenic cohort and the sex-, age-matched referents via
Monte Carlo simulation from the national life table. The monthly survival probability was multiplied by the av-
erage healthcare expenditures and summed throughout life to estimate the lifelong cost reimbursed by the Na-
tional Health Insurance. The results showed that patients diagnosed at age 20–29 had the highest expected years
of life lost (EYLL), 15 and 9 years, in men and women, respectively, with corresponding lifetime healthcare ex-
penditures ofUSD48,000 and53,000.Males generally had higher health cost per life-year than their female coun-
terparts across their lifespan. We applied the same method to the ﬁrst 6 years of the cohort and extrapolated to
12 years, which showed that the relative biases for different age stratawere less than 5%.We thus concluded that
the semi-parametric extrapolation method might provide a timely estimation of lifetime outcomes for health
care planning of schizophrenia.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Life expectancy
Expected years of life lost
Lifetime health care costs
Schizophrenia
Statistical method1. Introduction
Schizophrenia is, in many cases, chronic and disabling. Accelerating
and validating the estimation of lifetime outcomes becomes timely to
prioritize individual and national health actions. The shortened life ex-
pectancy (LE), also called the expected years of life lost (EYLL), of
schizophrenia ranges from 7.8 to 22.5 years (Hannerz et al., 2001;
Kodesh et al., 2012; Laursen, 2011; Lawrence et al., 2013; Nielsen
et al., 2013; Nordentoft et al., 2013; Tiihonen et al., 2009) when com-
pared with the general population. Most of the above studies applied
life table methods on national prevalence data for years. However, life
table methods usually require large, longitudinal follow-up cohorts to
reﬂect a low incidence and chronic course of schizophrenia. Moreover,
long-term outcomes estimated from incidence or treatment-/policy-, College of Medicine, National
y 701, Taiwan.
. This is an open access article undernaïve patients would be more accurate for showing trends and social
impacts in comparison with those based on prevalent cohorts.
Costs of schizophrenia are important for healthcare resources alloca-
tion. Despite few reports on the lifetime costs of schizophrenia,
prevalence-based estimates are relatively popular. The yearly costs of
psychotic disorders, mostly schizophrenia, ranked the third among 19
brain disorders in 30 European countries in 2010 (Olesen et al., 2012).
Langley-Hawthorne (1997) calculated LE and lifetime costs of schizo-
phrenia by utilizing Markov models with various transitional probabili-
ties and related costs extracted from the literature. She projected a
mean LE of 31 years and approximate lifetime cost of onemillion dollars
(36% direct costs) per patient with schizophrenia in 1995 in Australia
(Langley-Hawthorne, 1997). However, these estimates of lifetime
costs are still waiting for corroboration.
We have developed a semi-parametricmethod to estimate a lifelong
survival function (Hwang and Wang, 1999), which can be multiplied
with the average monthly cost of treating patients with schizophrenia
to obtain lifetime costs. The method was mathematically veriﬁed to be
valid, if constant excess hazard can be assumed (Fang et al., 2007),the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (a) Logit transformation of the survival ratioW(t) between the survival functions of
male patients with schizophrenia, aged 20–29, and that of the age- and gender-matched
reference population generated by the Monte Carlo method. The two vertical dotted
lines mark the time period when the logit survival ratio data were used for
extrapolation. The bottom dotted line is the linear regression line. (b) Lifelong
extrapolation to estimate the life expectancy of the 20–29 schizophrenia cohort and the
corresponding reference.
98 C.H. Lêng et al. / Schizophrenia Research 171 (2016) 97–102andwas empirically demonstrated to estimate life expectancy (LE), and
by extension expected years of life lost (EYLL) on cancer cohorts with
high censored rates (Andersson et al., 2013; Liu et al., 2013). Recently,
it was also applied on cohorts of heroin users with relative accuracy
(Chang et al., 2015). This study aims to estimate the LE, EYLL, lifetime
healthcare expenditures, and cost-per-life year for a cohort of incident
cases of schizophrenia followed for 12 years in Taiwan.Table 1
Annual incidence rate per 100,000, age at diagnosis and gender of cohorts.
Schizophrenia
(ICD9: 295)
Gender Total number of new
cases during
2000–2010
Age at
diagnosis,
mean (SD)
Annual
incidence rate
(×100,000−1)
20–29 Male 6372 24.72(2.89) 30.21
Female 4197 24.85(2.84) 20.73
30–39 Male 6333 34.30(2.86) 30.47
Female 4645 34.42(2.89) 22.77
40–49 Male 3972 43.97(2.86) 19.52
Female 3908 44.27(2.87) 19.50
50–59 Male 1774 53.69(2.76) 12.53
Female 2431 53.77(2.81) 16.99
60–64 Male 402 61.88(1.44) 9.23
Female 624 61.73(1.36) 13.59
Cumulative
incidence rates
(CIR20–64)
Male 968.7
Female 864.12. Materials and methods
2.1. Schizophrenia cohort
The National Health Insurance (NHI) in Taiwanwas implemented in
1995; and since 2004, more than 99% of Taiwan citizens have been cov-
ered (National Health Insurance, 2005). The catastrophic illness system
of the NHI features an up-to-date list of severe illnesses, including
schizophrenia, and the systemwaives the co-payment for the treatment
of the listed diseases. Schizophrenia healthcare that follows the formal
guidelines in Taiwan is freely accessible to registered patients diagnosed
and validated with code 295 based on ICD-9-CM by at least two board-
certiﬁed psychiatrists. We identiﬁed a total of 58,665 patients with
schizophrenia ﬁrst registered with the NHI as catastrophic illness over
the period of 2000–2010. Among them, 38,429 patients were hospital-
ized for schizophrenia for the ﬁrst time. In the ﬁnal analysis, only
34,658 within the age range of 20–64 when registered were included
to determine if the assumption of constant excess hazard could be ful-
ﬁlled among various age groups. The enrollees were either censored at
death or at the end of 2011. Their survival statuswas veriﬁed by linkage
with the national mortality registry. The health care expenditures, in-
cluding the inpatient and outpatient expenditures attributed toschizophrenia and related comorbidities, were retrieved from the NHI
database. Age- and gender-stratiﬁed annual incidence rates were calcu-
lated by dividing the number of new cases during the 11-year period
with the total sum of the mid-year population of individual age- and
gender-speciﬁc strata.
2.2. Extrapolation of long-term survival for the schizophrenic cohort
We applied Kaplan–Meier's method to estimate the time-to-mortal-
ity of the schizophrenic cohort stratiﬁed by gender and age. Lifetime
survival function was estimated by a semi-parametric extrapolation
method developed by Hwang and Wang (Hwang et al., 1996; Hwang
and Wang, 1999; Hwang and Wang, 2004) and later mathematically
validated by Fang et al. (2007). Themethod is brieﬂy summarized as fol-
lows: ﬁrst, hypothetical age- and gender-speciﬁc referents for each pa-
tient with schizophrenia were simulated by the Monte Carlo method
conditioned on the hazard function of the life table in a given year in
Taiwan. Second, the survival ratio between schizophrenic patients and
referents at time t was calculated, and assumed to be one initially and
gradually converge to a constant, representing the excess hazard of
the premature mortality accompanying schizophrenia. Third, the sur-
vival ratio was then logit-transformed so that a simple linear regression
could be applied to approximate the temporal trend of the stabilized pe-
riod until the end of 2011. Accordingly, the slope of the regression line
was used to extrapolate the lifetime survival of schizophrenia patients
after the follow-up limit, allowing the life expectancy (LE) of an age-,
gender-speciﬁc cohort to be estimated by summing up the area under
the curve of the survival function throughout the patient's life. The boot-
strap method of repeated sampling for 100 iterations was used to com-
pute the mean standard error. Fig. 1(a) illustrates the slope of constant
excess hazard for extrapolation (a) inmale patients with schizophrenia,
aged 20–29. Shaded area of the projected survival curve indicates the
EYLL of 20–29 male patients (Fig. 1(b)). A software package developed
by Hwang's team was used for the computation, and can be freely
downloaded: Integration of Survival with Quality of Life. http://www.
stat.sinica.edu.tw/isqol/ (updated on Feb. 12, 2014).
2.3. Estimation of expected years of life lost and lifetime healthcare expen-
ditures for schizophrenia
We estimated two lifetime outcomes to assess the impact of schizo-
phrenia. First, the expected years of life lost (EYLL) was the difference in
LE between the schizophrenic cohort and the age- and gender-matched
hypothetical referents, as described above. The second indicatorwas the
average lifetime healthcare expenditure per person, forwhich the reim-
bursement data of the National Health Insurance from 2000 to 2010 in-
cluded all medical expenses attributed to schizophrenia. We stratiﬁed
the cohort by 10-year age and gender speciﬁc strata, and then calculated
Table 2
Life expectancy, expected years of life lost, and health care expenditures (USD) of schizophrenia stratiﬁed by sex and age.
Schizophrenia
(ICD9: 295)
Gender Number Life expectancy
Mean (SE) years
Expected years of life lost
Mean (SE) years
Life time healthcare expenditure/case
(3% discount)a
Cost per life year (PPP-adjusted)b
20–29 Male 6372 35.64(0.03) 15.17(0.04) 48,244 ± 3079 (42,741–54,557) 4061.73 (260.71)
Female 4197 47.17(0.04) 9.22(0.03) 53,411 ± 2905 (48,359–58,911) 3886.94 (212.56)
30–39 Male 6333 34.74(0.04) 7.28(0.03) 43,205 ± 2867 (38,628–49,179) 3754.46 (249.79)
Female 4645 40.99(0.05) 6.19(0.04) 46,260 ± 3097 (42,214–53,673) 3604.02 (242.19)
40–49 Male 3972 26.77(0.04) 6.66(0.04) 44,423 ± 2542 (40,112–50,528) 4530.65 (262.41)
Female 3908 29.48(0.05) 8.24(0.04) 44,229 ± 3009 (39,927–51,206) 4184.75 (286.25)
50–59 Male 1774 18.4(0.08) 6.9(0.08) 38,791 ± 2010 (36,320–43,755) 5126.53 (259.77)
Female 2431 21.34(0.05) 7.66(0.06) 38,214 ± 1793 (34,793–41,024) 4468.32 (209.34)
60–64 Male 402 14.44(0.2) 4.50(0.20) 34,279 ± 2130 (30,527–38,431) 5536.98 (348.23)
Female 624 17.77(0.14) 4.21(0.14) 37,568 ± 1434 (35,136–40,864) 5110.21 (211.74)
a 1USD$ = 29.322 New Taiwan Dollars (NTD) on December 31, 2010.
b Purchasing Power Parities (PPP) adjusted exchange rate: 1USD= 16.83 NTD (2010, https://www.imf.org).
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of all survived patients with the number of survived patients at that
month, of which the expenditure was ﬁrst adjusted to the nominal ex-
change rate of 1USD=29.322 New TaiwanDollars (NTD) on December
31, 2010. Then, we multiplied the average monthly expenditure by the
corresponding survival probability and summed up over a lifetime to
obtain lifelong cost. The extrapolated costswere adjustedwith an annu-
al discount rate of 3%.We also obtained the cost per life year by dividing
the lifetime expenditurewith the discounted LE, 3% per year, for consis-
tency. To bemore comparable internationally, the cost per life-yearwas
adjusted according to the purchasing power parities (PPP) implied ex-
change rate: 1USD = 16.83 NTD, (International Monetary Fund.
http://www.imf.org) in 2010.
2.4. Validation of the extrapolation method
We validated our extrapolation method as follows: The ﬁrst 6-year
follow-up data (registered during 2000–2005) was extrapolated for
6 years to estimate the 12-year LE, which were compared with the
Kaplan–Meier estimate based on the actual 12-year follow-up to the
end of 2011. Namely, out-of-sample predictive validity tests were
based on comparing predictions for the remaining 6 years of data with-
held from themodel-building exercisewith the actual observed data. In
addition, every graph of logit transformed survival ratiowas plotted and
examined if the assumption of constant excess hazardwas fulﬁlled near
the end of 12-year follow-up.
3. Results
The 34,658 patients with schizophrenia were stratiﬁed by gender
and age. The total number of subjects,meanof diagnosis age, and annual
incidence rate of each age- and gender-speciﬁc group are summarizedTable 3
Validation of the extrapolated estimates according to 6 years of follow-up and the Kaplan–Mei
Schizophrenia
(ICD9: 295)
Gender Cohort
size
Registered
age (SD)
Censored
rate (%)
12(2000–2011)-
Kaplan–Meie
Mean (SE)
20–29 Male 4385 24.58 (2.89) 98.02 11.50 (
Female 2795 24.74 (2.86) 98.10 11.54 (
30–39 Male 4297 34.35 (2.84) 96.02 11.08 (
Female 2825 34.47 (2.90) 97.52 11.44 (
40–49 Male 2628 43.90 (2.83) 94.71 10.76 (
Female 2503 44.20 (2.88) 96.56 11.18 (
50–59 Male 1005 53.54 (2.76) 92.24 10.00 (
Female 1470 53.61 (2.83) 95.71 10.79 (
60–64 Male 245 62.02 (1.43) 86.12 8.64 (0
Female 411 61.75 (1.35) 91.73 9.80 (0
a Relative bias = (estimate from extrapolation – K–M estimate) / K–M estimate.in Table 1. Males ﬁrst registering their schizophrenia as a catastrophic
illness peaked at a younger age than for females.
3.1. Estimation of life expectancy (LE) and expected years of life lost (EYLL)
Stratiﬁed by age and gender, Table 2 summarizes the LE, EYLL, life-
time healthcare costs, and cost per life year. On average, males with
schizophrenia had higher EYLL's than did females, except for the 40–
59 age group. Males aged 20–29 had the highest EYLL, 15.17 years,
and dropped to approximately 6–7 years if onset at the age of 30–59. Fe-
male patients aged 20–29 had the ﬁrst EYLL peak of 9.2 years, while the
second EYLL peak of 7–8 years occurred for the 40–59 year-old females.
3.2. Lifetime healthcare expenditures and cost per life year
Table 2 illustrates the estimated life time healthcare expenditures
with 3% discount (USD), and PPP-adjusted cost per life yearwith 3% dis-
count on both costs. The highest lifetime expenditures were $48,244 ±
3079 for males aged 20–29; this ﬁgure descended to a plateau of ap-
proximately $43,000–$44,000 before age 50, and then gradually de-
creased as the registering age increased. Despite the similar LE of
35 years for both the 20–29 and 30–39 male groups, the younger
group cost $5039 more in lifetime health expenditures than did the
30–39 group. This might imply a difference in the illness severity in
the younger onset groups despite a similar chronicity. By contrast, fe-
male patients with schizophrenia who registered at 20–39 had longer
life expectancies and higher overall lifetime expenditures than their
male counterparts. Females who registered at the age of 20–29 had
the highest lifetime costs, $53,411 ± 2905, among all gender and age
groups. After age 40, their lifetime expenditures were similar to those
of the same age male groups and also decreased according to age. Fur-
thermore, health expenditure per life year ranged from USD$3600 toer method.
year follow-up
r estimate
months
Estimate using the extrapolation based on the
ﬁrst 6 years of follow-up
Mean (SE) months
Relative biasa
%
0.03) 11.53 (0.01) 0.30
0.04) 11.62 (0.01) 0.66
0.04) 11.26 (0.01) 1.57
0.04) 11.43 (0.01) −0.06
0.06) 10.79 (0.03) 0.32
0.05) 11.30 (0.02) 1.03
0.12) 10.42 (0.05) 4.18
0.07) 11.20 (0.02) 3.82
.27) 8.14 (0.13) −5.81
.16) 9.54 (0.06) −2.63
100 C.H. Lêng et al. / Schizophrenia Research 171 (2016) 97–102$5550 (PPP-adjusted). Moreover, healthcare expenditures per person
year generally increased as the subjects aged.
3.3. Validation of the semi-parametric method
Table 3 indicates the differences between the semi-parametric ex-
trapolation of 6 years based on the ﬁrst 6 years and the observed 12-
year LE. The relative biases were less than 5% in all gender-age groups,
with the exception of males aged 60–64, who had a 5.81% relative
bias, an absolute difference of 0.5 year, and the lowest censored rate
(86.12%). Notably, as the sample size decreased, the relative bias
seemed less stable. Fig. 2 illustrates the constant excess hazard of each
stratiﬁed age and gender stratum. The assumption of constant excessFig. 2. The survival rate ratioW(t) between the patients with schizophrenia and that of the age
plotted against time after diagnosis. It converges to a straight line for all the 10 different age and
and the assumption is fulﬁlled. The two dotted lines mark the time period when the slope of lhazard appears to be satisﬁed among the patients aged 20–64 be-
cause the logit transformation of the survival ratio between patients
with schizophrenia and the age- and gender-matched referents
shows a linear trend and estimable slope approximately 1–2 years
after diagnosis.
4. Discussion
This study reveals that onset of schizophrenia appears to be associat-
ed with substantial EYLL, ranging from 6 to 15 years, while associated
lifetime healthcare expenditures range from USD 38,000 to 53,000 per
person (Table 2). Both estimates depend heavily on accurate estimation
of the lifetime survival function of the schizophrenic cohort. Thus, we- and gender-matched referents was transformed into logit (W(t) / (1−W(t))), which is
gender strata after the initial period of 1–2 years, indicating constant excess hazard exists
ogit of survival ratio was used for extrapolation.
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tion before making any further inferences. Onset of schizophrenia cas-
cades a series of acute and chronic physical and psychosocial
difﬁculties. As the course stabilizes, evaluation of long-term outcomes
might require extrapolation beyond the limited follow-up time. To con-
sider both the excess hazard associated with schizophrenia and the
background hazard of the general population, we graphed the logit-
transformed relative survival and ﬁt a regression line along the
temporally-stabilized period near the end of 12-year of follow-up for
extrapolation (Figs. 1(a) and 2). The relative bias estimated by our
semi-parametric extrapolation seems robust when compared with the
Kaplan–Meier estimates after 12 years of real follow-up (Table 3). To
control the cohort effect due to competing risks of mortality or long-
term side effects of medication, we used incidence cases and stratiﬁed
themby age and gender. Our analysis shows that cohorts of schizophre-
nia generally fulﬁll the assumption of constant excess hazard, namely,
there is an estimable slope of logit of survival ratio (W(t)) after the
ﬁrst several years, which have lasted up to 12 years (Figs. 1(a) and 2).
Since we have stratiﬁed our cohorts into every 10-year age period, we
would expect that such a constant excess mortality would lead to the
next 10-year age periods and our extrapolation would most likely be
valid. Accordingly, the estimated lifetime health expenditures paid by
the NHI of Taiwan would also be relatively accurate.
The sex ratio and incidence rates of schizophrenia in Taiwan
(Table 1) seem similar to those reported from other countries
(McGrath et al., 2004). The EYLL were found to be 15.17 and
9.22 years for male and female, respectively, for schizophrenia aged
20–29 (Table 2). As our cohort did not include schizophrenia diagnosed
below age 20, who are expected to have an even higher EYLL, we be-
lieved that the overall estimates would be similar to those reported by
several western countries, for example, 14.6 in southeast London
(Chang et al., 2011), 15.3–20.1 in Denmark (Laursen, 2011; Nielsen
et al., 2013; Nordentoft et al., 2013), 12.8–22.5 in Finland (Nordentoft
et al., 2013; Tiihonen et al., 2009; Westman et al., 2012), and 16.4 in
Western Australia (Lawrence et al., 2013). The EYLL for age over 30 ap-
pear to be more stabilized and smaller than that of the younger age
group, which corroborates a previous study (Chen et al., 1996). Because
Taiwan is a small island with 36,000 km2 and has implemented a uni-
versal coverage healthcare system since 1995, residents can generally
access healthcare services within two hours of transportation. The
above unique condition may have lowered down mortality of acute
care (Wen et al., 2008), including suicide or infections (Nordentoft
et al., 2013), and possibly schizophrenia related illnesses (Laursen,
2011; Nielsen et al., 2013). Nevertheless, future studies of stratifyingdif-
ferent causes of mortality are warranted to corroborate the above
hypothesis.
Patients with schizophrenia onset before age 50, had relatively high
lifetime healthcare costs, ranging fromUSD 43,000 to 49,000 per person
(Table 2). The lifetime costs would be underestimated for some pa-
tients, however, because the NHI restricted the hospitalized patients
to no more than 6 months and some patients would be transferred to
nursing homes and switch to the use of social welfare resources for a
short period of time. The reimbursement frommost psychiatric nursing
homes was from the Department of Social Affairs, Ministry of the Interi-
or before 2012, and is not included in the present study. But the reim-
bursement of medication is still paid by the NHI. Furthermore, divided
by discounted LE, healthcare costs per life year ranged from USD 3600
to 5500 (PPP-adjusted), while the corresponding costs ranged from
€5102–7068 (€PPP, 2010) in France, Germany, Spain, and the UK
(Gustavsson et al., 2011). Adjusting for PPP decreased the disparity. In
addition to yearly estimation, our approximated lifelong costs could bol-
ster a comprehensive long-term care or budget plans.
This study has at least the following limitations. First, the registered
age, however, is used as a proxy of the onset for all patients, which
would result in underestimation of EYLL because of possible registry de-
lays. Since all registered patientswith schizophrenia arewaived from allcopayments, the ﬁnancial incentive generally reduces such a potential
bias to a minimum. Second, we have not systematically collected any
data related to out-of-pocket costs (Lee et al., 2008). As patients with
schizophrenia usually receive numerous alternative and complimentary
treatments in traditional Taiwanese culture, such a discrepancy should
not be ignored and future studies must include this portion when tally-
ing social costs.
In conclusion, we have successfully applied a novel semi-parametric
extrapolation to estimate gender- and age- speciﬁc LE, EYLL, and the
lifetime healthcare expenditures for schizophrenia in Taiwan. The strat-
egy of thismethod is based on follow-up formore than 10–12 years and
stratiﬁcation of a cohort into every 10-year age strata to examine if con-
stant excess mortality exists in each age strata. And it could also be ap-
plied in other serious mental illnesses leading to premature mortality,
e.g., bipolar disorder and/or major depression. Schizophrenia ﬁrst diag-
nosed at age 20–29 had the highest EYLL, 15 and 9 years, as well as the
largest lifetimehealthcare expenditures, USD 48,000 and 53,000, inmen
andwomen, respectively. Future studies are indicated for longer follow-
up terms and data collection of out-of-pocket money to determine the
entire burden to society.
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